IP Library Granted Patent US 8,771,701
Granted Patent B2
US 8,771,701 · App. 11/561,204 · Granted Jul 8, 2014

Compositions for immunotherapy and uses thereof

Inventors: Ian F. C. McKenzie (Brunswick, AU); Vasso Apostolopoulos (St. Albans, AU); Geoffrey A. Pietersz (Greensborough, AU)
Assignee: MacFarlane Burnet Institute for Medical Research and Public Health Ltd
A61K39/0011A61K2039/6087A61K2039/57C12N2501/23C12N2501/22C12N2501/25C12N5/0645A61K2039/5154A61K39/385C12N2500/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,771,701
App. No.
11/561,204
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.

Claims (10)

1. A method of eliciting a cytotoxic T lymphocyte response in an human to an antigen selected from the group consisting of a mucin polypeptide, one or more repeated subunits thereof and an antigenic fragment of said repeated subunits, said fragment comprising at least 5 amino acids of said repeated subunits, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising said antigen and a carbohydrate polymer wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes, and wherein said pulsing results in binding of said conjugate to said mannose receptor, and wherein said binding results in internalizing, processing and presenting of said antigen on said antigen presenting cells; and administering the pulsed antigen presenting cells to said human.

2. The method of claim 1 , wherein said mannose receptor-bearing antigen presenting cells are derived from a cell population selected from the group consisting of peripheral blood leukocytes, bone marrow, stem cells, peritoneal cells, spleen, lung and lymph node cells.

3. The method of claim 1 , wherein said mannose receptor-bearing antigen presenting cells are selected from the group consisting of macrophage cells and dendritic cells.

4. The method of claim 1 , wherein said mannose receptor-bearing cells comprise antigen presenting cells that express molecules selected from the group consisting of CD11b, CD14, CD68, CD80 and CD86.

5. The method of claim 1 , wherein said mannose receptor-bearing antigen presenting cells comprise cells that have been contacted with one or more biological response modifiers selected from the group consisting of a cytokine and a vitamin under conditions effective to induce expression of carbohydrate receptors by said cells.

6. The method of claim 5 , wherein said biological response modifiers induce expression of mannose receptors on said antigen presenting cell.

7. The method of claim 5 , wherein said biological response modifiers are selected from the group consisting of granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3, interleukin-4, vitamin D, macrophage colony stimulating factor (M-CSF), Flt-3 ligand and tumor necrosis factor (TNF) alpha.

8. The method of claim 1 , wherein said mucin is human mucin.

9. The method of claim 1 , wherein said antigen comprises two to eighty copies of said repeated subunits of human mucin.

10. The method of claim 1 , wherein said one or more repeated subunits of said antigen comprise part of a fusion polypeptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2011
From: MCKENZIE, IAN F.C.; APOSTOLOPOULOS, VASSO; PIETERSZ, GEOFFREY A.
To: THE AUSTIN RESEARCH INSTITUTE
Reel/Frame 026127/0530 →
MERGER Recorded Apr 14, 2011
From: THE AUSTIN RESEARCH INSTITUTE
To: MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
Reel/Frame 026127/0834 →
Continuity (3)
Division 09163089 · Sep 29, 1998
Provisional Application 60060594 · Sep 29, 1997
Related Publication 20070071765A1 · Mar 29, 2007